Copyright
©The Author(s) 2023.
World J Gastroenterol. Mar 28, 2023; 29(12): 1824-1837
Published online Mar 28, 2023. doi: 10.3748/wjg.v29.i12.1824
Published online Mar 28, 2023. doi: 10.3748/wjg.v29.i12.1824
Figure 1 Digoxin reduces steatohepatitis by suppressing pyruvate kinase M2 dependent hypoxia-inducible factor 1-alpha activity and inhibiting reactive oxygen species production[27,28].
Digoxin structure derived from MolView. HIF-1α: Hypoxia-inducible factor 1-alpha; PKM2: Pyruvate kinase M2; ROS: Reactive oxygen species.
- Citation: Jamshed F, Dashti F, Ouyang X, Mehal WZ, Banini BA. New uses for an old remedy: Digoxin as a potential treatment for steatohepatitis and other disorders. World J Gastroenterol 2023; 29(12): 1824-1837
- URL: https://www.wjgnet.com/1007-9327/full/v29/i12/1824.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i12.1824